CELESTODERM V OINTMENT

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

BETAMETHASONE (BETAMETHASONE VALERATE)

Disponibbli minn:

BAUSCH HEALTH, CANADA INC.

Kodiċi ATC:

D07AC01

INN (Isem Internazzjonali):

BETAMETHASONE

Dożaġġ:

0.1%

Għamla farmaċewtika:

OINTMENT

Kompożizzjoni:

BETAMETHASONE (BETAMETHASONE VALERATE) 0.1%

Rotta amministrattiva:

TOPICAL

Unitajiet fil-pakkett:

450G

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANTI-INFLAMMATORY AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0106299001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2014-10-10

Karatteristiċi tal-prodott

PRESCRIBING INFORMATION
PR
CELESTODERM
® V
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.1%
PR
CELESTODERM
® V/2
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.05%
TOPICAL CORTICOSTEROID
September
29
,
2020
DATE OF
REVISION:
Control
#:
242776
H7L 4A8
Laval, Quebec
2150 St-Elzear
Blvd. West
,
BAUSCH HEALTH, CANADA INC.
_ _
_Pr_
_CELESTODERM _
_®_
_ V and CELESTODERM_
_®_
_ V/2 Prescribing Information Page 2 of 10_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS…………………………………………………......4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
............................................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
_ _
_Pr_
_CELESTODERM _
_®_
_ V and CELESTODERM_
_®_
_ V/2 Prescribing Information Page 3 of 10_ PR
CELESTODERM
® V
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.1%
PR
CELESTODERM
® V/2
Betamethasone valerate cream USP
Betamethasone val